DART: of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).

• Sponsor: AstraZeneca (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00925717
• Collaborator: (none)
• Enrollment: 4,045
• Locations: 24
• Duration (Months): 5
• Patients Per Site: 168.5
• Patients Per Site Per Month: 33.5

Study Details

Study Description

Brief Summary

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.

Condition or Disease	Intervention/Treatment	Phase
Low Density Lipoprotein Cholesterol Goal Achievement

Study Design

• Study Type: Observational
• Actual Enrollment: 4045 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
• Study Start Date: May 1, 2009
• Actual Study Completion Date: Oct 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
2500 patients Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

Outcome Measures

Primary Outcome Measures

1. Investigate LDL-C goal achievement rate according to ADA recommendation [Within the last 6 months from the date of data entry.]

Secondary Outcome Measures

1. Investigate reduction of 10-year risk for CHD by using UKPDS risk engine [Within the last 6 months from the date of data entry.]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Subjects who was diagnosed as diabetes

• Subjects who was diagnosed as dyslipidaemia or takes lipid lowering medication

• Clinic visit in the past 6 months more than once

Exclusion Criteria:

• Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Cheonan-si	Chungchungnam-do	Korea, Republic of
2	Research Site	Ansan-si	Gyeonggi-do	Korea, Republic of
3	Research Site	Anyang-si	Gyeonggi-do	Korea, Republic of
4	Research Site	Bucheon-si	Gyeonggi-do	Korea, Republic of
5	Research Site	Goyang-si	Gyeonggi-do	Korea, Republic of
6	Research Site	Seongnam-si	Gyeonggi-do	Korea, Republic of
7	Research Site	Suwon-si	Gyeonggi-do	Korea, Republic of
8	Research Site	Uijeongbu-si	Gyeonggi-do	Korea, Republic of
9	Research Site	Gwangju-si	Jeollanam-do	Korea, Republic of
10	Research Site	Suncheon	Jeollanam-do	Korea, Republic of
11	Research Site	Jeonju-si	Jeonllabuk-do	Korea, Republic of
12	Research Site	Chuncheon-si	Kangwon-do	Korea, Republic of
13	Research Site	Chuncheon	Kangwon-do	Korea, Republic of
14	Research Site	Kang-Neung	Kangwon-do	Korea, Republic of
15	Research Site	Wonju-si	Kangwon-do	Korea, Republic of
16	Research Site	Busan-si		Korea, Republic of
17	Research Site	Cheonju-si		Korea, Republic of
18	Research Site	Daegu-si		Korea, Republic of
19	Research Site	Daejeon-si		Korea, Republic of
20	Research Site	Incheon-si		Korea, Republic of
21	Research Site	Incheon		Korea, Republic of
22	Research Site	Jeonju-si		Korea, Republic of
23	Research Site	Kwangju-si		Korea, Republic of
24	Research Site	Seoul		Korea, Republic of

Sponsors and Collaborators

• AstraZeneca

Investigators

• Study Director: MoonGyu Lee, Ph.D., Samsung Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00925717
• Other Study ID Numbers: NIS-CKR-DUM-2009/1
• First Posted: Jun 22, 2009
• Last Update Posted: Jan 26, 2010
• Last Verified: Jan 1, 2010

• Keywords provided by , ,: ADA recommendation
• Additional relevant MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2

Study Results

No Results Posted as of Jan 26, 2010